| Assessment Status | Rapid Review Complete |
| HTA ID | 23020 |
| Drug | Pegunigalsidase alfa |
| Brand | Elfabrio® |
| Indication | Pegunigalsidase alfa (Elfabrio®) is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase). |
| Assessment Process | |
| Rapid review commissioned | 19/04/2023 |
| Rapid review completed | 24/05/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that pegunigalsiadase alfa not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
